NEW YORK (GenomeWeb News) – Insight Genetics today announced it was awarded a $1.5 million Phase II Small Business Innovation Research contract from the National Cancer Institute to continue development of a diagnostic test aimed at non-small cell lung cancer.

The Fast Track contract will go toward the further development of a panel of assays for identifying and characterizing ongogenic ROS1, RET, and DEPDC1 in a population of NSCLC patients who are triple negative for mutations in EGFR, KRAS, or ALK, the Nashville, Tenn.-based company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.